


WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:



wherein:

R^1 is an unsubstituted or a substituted C_2 alkenyl, an unsubstituted or a substituted C_2 alkynyl, an unsubstituted or a substituted monocyclic heteroaryl, an unsubstituted or a substituted bicyclic heteroaryl or an unsubstituted or a substituted monocyclic heterocyclyl, wherein when the C_2 alkenyl, the C_2 alkynyl, an unsubstituted C_{1-4} haloalkyl and the monocyclic heteroaryl are substituted, the C_2 alkenyl, the C_2 alkynyl and the monocyclic heteroaryl are independently substituted with one or more substituents selected from the group consisting of halogen, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted C_{1-4} hydroxyalkyl, an unsubstituted monocyclic C_{3-6} cycloalkyl and a hydroxy-substituted monocyclic C_{3-6} cycloalkyl;

R^2 and R^3 are independently selected from the group consisting of hydrogen, an unsubstituted or a substituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl, an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, an unsubstituted C_{1-4} hydroxyalkyl and an unsubstituted C_{1-5} alkoxyalkyl, wherein when the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are substituted, the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are independently substituted with one or more substituents selected from the group consisting of halogen or hydroxy, and wherein when the C_{1-4} alkyl is substituted, the C_{1-4} alkyl is substituted with one or more substituents selected from the group consisting of a phosphate, an O-linked α -amino acid and an O-carboxy, and provided that at least one of R^2 and R^3 is not hydrogen; or

R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl or an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, wherein when the C_{3-6} cycloalkyl and 3-6 membered heterocyclyl are substituted, the C_{3-6} cycloalkyl and the 3-6 membered heterocyclyl are independently substituted with 1 or 2 substituents selected from the group consisting of halogen and hydroxy;

R^4 and R^5 are independently hydrogen, halogen, an unsubstituted C_{1-4} alkyl, a deuterated C_{1-4} alkyl or an unsubstituted C_{2-4} alkenyl;

R^6 is hydrogen, an unsubstituted C_{1-4} alkyl, a deuterated C_{1-4} alkyl or an unsubstituted C_{3-4} alkenyl; and

provided that at least one of R^4 , R^5 and R^6 is not hydrogen; or

R^5 is hydrogen, halogen, an unsubstituted C_{1-4} alkyl or an unsubstituted C_{2-4} alkenyl; and R^4 and R^6 are taken together to form an unsubstituted or substituted 5-6 membered heterocyclic ring;

X^1 is CR^A or N;

R^{7a} , R^{7b} , R^{7c} and R^{7d} are independently hydrogen, halogen, an unsubstituted C_{1-4} haloalkyl, cyano or an unsubstituted C_{1-4} alkoxy;

R^8 is hydrogen, $-CH_2OC(=O)-(an\ unsubstituted\ C_{1-4}\ alkyl)$, $-CH_2OC(=O)-O(an\ unsubstituted\ C_{1-4}\ alkyl)$, $-CH_2-(\alpha\text{-amino acid})$ or $-CH_2\text{-phosphate}$; and

R^A is hydrogen, halogen, an unsubstituted C_{1-4} haloalkyl or cyano.

2. The compound of Claim 1, wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl, an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, an unsubstituted C_{1-4} hydroxyalkyl and an unsubstituted C_{1-5} alkoxyalkyl, wherein when the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are substituted, the monocyclic C_{3-6} cycloalkyl and the monocyclic 3-6 heterocyclyl are independently substituted with one or more substituents selected from the group consisting of halogen or hydroxy.

3. The compound of Claim 2, wherein R^2 and R^3 are each an unsubstituted C_{1-4} alkyl.

4. The compound of Claim 1, wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, a substituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted or a substituted monocyclic C_{3-6} cycloalkyl, an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, an unsubstituted C_{1-4} hydroxyalkyl and an unsubstituted C_{1-5} alkoxyalkyl, wherein the C_{1-4} alkyl is substituted with one or more substituents selected from the group consisting of a phosphate, an O-linked α -amino acid and an O-carboxy.
5. The compound of any one of Claims 1-4, wherein one of R^2 and R^3 is hydrogen.
6. The compound of Claim 5, wherein the other of R^2 and R^3 is an unsubstituted C_{1-4} alkyl.
7. The compound of Claim 5, wherein the other of R^2 and R^3 is a substituted C_{1-4} alkyl, wherein when the C_{1-4} alkyl is substituted, the C_{1-4} alkyl is substituted with one or more substituents selected from the group consisting of a phosphate, an O-linked α -amino acid and an O-carboxy.
8. The compound of Claim 5, wherein the other of R^2 and R^3 is an unsubstituted C_{1-4} haloalkyl.
9. The compound of Claim 5, wherein the other of R^2 and R^3 is an unsubstituted monocyclic C_{3-6} cycloalkyl.
10. The compound of Claim 5, wherein the other of R^2 and R^3 is a substituted monocyclic C_{3-6} cycloalkyl.
11. The compound of Claim 5, wherein the other of R^2 and R^3 is an unsubstituted monocyclic 3-6 membered heterocyclyl.
12. The compound of Claim 5, wherein the other of R^2 and R^3 is a substituted monocyclic 3-6 membered heterocyclyl.
13. The compound of Claim 5, wherein the other of R^2 and R^3 is an unsubstituted C_{1-4} hydroxyalkyl.
14. The compound of Claim 5, wherein the other of R^2 and R^3 is an unsubstituted C_{1-5} alkoxyalkyl.
15. The compound of Claim 1, wherein R^2 and R^3 are taken together along with the carbon to which R^2 and R^3 are attached to form an unsubstituted or a substituted

monocyclic C₃₋₆ cycloalkyl or an unsubstituted or a substituted monocyclic 3-6 membered heterocyclyl, wherein when the C₃₋₆ cycloalkyl and 3-6 membered heterocyclyl are substituted, the C₃₋₆ cycloalkyl and the 3-6 membered heterocyclyl are independently substituted with 1 or 2 substituents selected from the group consisting of halogen and hydroxy.






16. The compound of Claim 15, wherein R² and R³ are taken together along with the carbon to which R² and R³ are attached to form an unsubstituted monocyclic C₃₋₆ cycloalkyl.

17. The compound of Claim 15, wherein R² and R³ are taken together along with the carbon to which R² and R³ are attached to form a substituted monocyclic C₃₋₆ cycloalkyl

18. The compound of Claim 55, wherein R² and R³ are taken together along with the carbon to which R² and R³ are attached to form an unsubstituted monocyclic 3-6 membered heterocyclyl.

19. The compound of Claim 15, wherein R² and R³ are taken together along with the carbon to which R² and R³ are attached to form a substituted monocyclic 3-6 membered heterocyclyl.

20. The compound of Claim 18 or 19, wherein the monocyclic 3-6 membered heterocyclyl is selected from the group consisting of an unsubstituted or substituted oxetane,

an unsubstituted or substituted thietane, an unsubstituted or substituted , an unsubstituted or substituted , an unsubstituted or substituted , an unsubstituted or substituted , an unsubstituted or substituted  and an unsubstituted or substituted .


21. The compound of any one of Claims 1-20, wherein R⁴ is hydrogen.


22. The compound of any one of Claims 1-20, wherein R^4 is halogen.
23. The compound of any one of Claims 1-20, wherein R^4 is an unsubstituted C_{1-4} alkyl.
24. The compound of any one of Claims 1-20, wherein R^4 is a deuterated C_{1-4} alkyl.
25. The compound of any one of Claims 1-24, wherein R^5 is hydrogen.
26. The compound of any one of Claims 1-24, wherein R^5 is halogen.
27. The compound of any one of Claims 1-24, wherein R^5 is an unsubstituted C_{1-4} alkyl.
28. The compound of any one of Claims 1-27, wherein R^6 is an unsubstituted C_{1-4} alkyl.
29. The compound of any one of Claims 1-27, wherein R^6 is an unsubstituted C_{3-4} alkenyl.
30. The compound of any one of Claims 1-20, wherein R^5 is hydrogen; and R^4 and R^6 are taken together to form an unsubstituted or substituted 5-6 membered heterocyclic ring.
31. The compound of any one of Claims 1-20, wherein R^5 is halogen; and R^4 and R^6 are taken together to form an unsubstituted or substituted 5-6 membered heterocyclic ring.
32. The compound of any one of Claims 1-20, wherein R^5 is an unsubstituted C_{1-4} alkyl; and R^4 and R^6 are taken together to form an unsubstituted or substituted 5-6 membered heterocyclic ring.
33. The compound of any one of Claims 1-20, wherein R^5 is an unsubstituted C_{2-4} alkenyl; and R^4 and R^6 are taken together to form an unsubstituted or substituted 5-6 membered heterocyclic ring.
34. The compound of any one of Claims 1-33, wherein X^1 is N.
35. The compound of any one of Claims 1-33, wherein X^1 is CR^A .
36. The compound of Claim 35, wherein R^A is hydrogen.
37. The compound of Claim 35, wherein R^A is halogen.
38. The compound of Claim 35, wherein R^A is an unsubstituted C_{1-4} haloalkyl.
39. The compound of Claim 35, wherein R^A is cyano.
40. The compound of Claim 35, wherein R^A is an unsubstituted C_{1-4} alkoxy.


41. The compound of any one of Claims 1-40, wherein R^{7a} is hydrogen.
42. The compound of any one of Claims 1-40, wherein R^{7a} is halogen.
43. The compound of any one of Claims 1-40, wherein R^{7a} is an unsubstituted C_{1-4} haloalkyl.
44. The compound of any one of Claims 1-40, wherein R^{7a} is cyano.
45. The compound of any one of Claims 1-40, wherein R^{7a} is an unsubstituted C_{1-4} alkoxy.
46. The compound of any one of Claims 1-45, wherein R^{7b} is hydrogen.
47. The compound of any one of Claims 1-45, wherein R^{7b} is halogen.
48. The compound of any one of Claims 1-45, wherein R^{7b} is an unsubstituted C_{1-4} haloalkyl.
49. The compound of any one of Claims 1-45, wherein R^{7b} is cyano.
50. The compound of any one of Claims 1-45, wherein R^{7b} is an unsubstituted C_{1-4} alkoxy.
51. The compound of any one of Claims 1-50, wherein R^{7c} is hydrogen.
52. The compound of any one of Claims 1-50, wherein R^{7c} is halogen.
53. The compound of any one of Claims 1-50, wherein R^{7c} is an unsubstituted C_{1-4} haloalkyl.
54. The compound of any one of Claims 1-50, wherein R^{7c} is cyano.
55. The compound of any one of Claims 1-50, wherein R^{7c} is an unsubstituted C_{1-4} alkoxy.
56. The compound of any one of Claims 1-55, wherein R^{7d} is hydrogen.
57. The compound of any one of Claims 1-55, wherein R^{7d} is halogen.
58. The compound of any one of Claims 1-55, wherein R^{7d} is an unsubstituted C_{1-4} haloalkyl.
59. The compound of any one of Claims 1-55, wherein R^{7d} is cyano.
60. The compound of any one of Claims 1-55, wherein R^{7d} is an unsubstituted C_{1-4} alkoxy.
61. The compound of any one of Claims 1-60, wherein R^1 is an unsubstituted C_2 alkenyl.


62. The compound of any one of Claims 1-60, wherein R^1 is a substituted C_2 alkenyl.
63. The compound of any one of Claims 1-60, wherein R^1 is an unsubstituted C_2 alkynyl.
64. The compound of any one of Claims 1-60, wherein R^1 is a substituted C_2 alkynyl.
65. The compound of any one of Claims 1-60, wherein R^1 is an unsubstituted C_{1-4} haloalkyl.
66. The compound of any one of Claims 1-60, wherein R^1 is an unsubstituted monocyclic heteroaryl.
67. The compound of any one of Claims 1-60, wherein R^1 is a substituted monocyclic heteroaryl.
68. The compound of any one of Claims 1-60, wherein R^1 is an unsubstituted bicyclic heteroaryl.
69. The compound of any one of Claims 1-60, wherein R^1 is a substituted bicyclic heteroaryl.
70. The compound of any one of Claims 1-60, wherein R^1 is an unsubstituted monocyclic heterocyclyl.
71. The compound of any one of Claims 1-60, wherein R^1 is a substituted monocyclic heterocyclyl.
72. The compound of any one of Claims 1-71, wherein R^8 is hydrogen.
73. The compound of any one of Claims 1-71, wherein R^8 is $-\text{CH}_2\text{OC}(=\text{O})-$ (an unsubstituted C_{1-4} alkyl).
74. The compound of any one of Claims 1-71, wherein R^8 is $-\text{CH}_2\text{OC}(=\text{O})-\text{O}$ (an unsubstituted C_{1-4} alkyl).
75. The compound of any one of Claims 1-71, wherein R^8 is $-\text{CH}_2-(\alpha\text{-amino acid})$.
76. The compound of any one of Claims 1-71, wherein R^8 is $-\text{CH}_2\text{-phosphate}$.


77. The compound of Claim 1, wherein the compound is selected from the group consisting of:



















78. The compound of Claim 1, wherein the compound is selected from the group consisting of :















the foregoing.

79. The compound of Claim 78 or 79, wherein the compound is selected from the group consisting of :












, or a pharmaceutically acceptable salt of

any of the foregoing.

80. A compound is selected from the group consisting of :





and , or a pharmaceutically acceptable salt of any of the foregoing.

81. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-80, or a pharmaceutically acceptable salt thereof, and excipient.

82. Use of the compound of any one of Claims 1-80 in the preparation of a medicament for the treatment of hepatitis B.

83. Use of the compound of any one of Claims 1-80 in the preparation of a medicament for the treatment of hepatitis D.

84. The use of any one of Claims 82-83, wherein the use further comprises the use of one or more additional agents selected from the group consisting of an interferon, a

nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator.

85. The use of Claim 84, wherein the one or more additional agents are selected from the group consisting of recombinant interferon alpha 2b, IFN- α , PEG-IFN- α -2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil.

86. A compound of any one of Claims 1-80 for use in treating hepatitis B.

87. A compound of any one of Claims 1-80 for use in treating hepatitis D.

88. The compound of any one of Claims 86-87, wherein the compound is used in combination with one or more additional agents selected from the group consisting of an interferon, a nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator.

89. The compound of Claim 88, wherein the one or more additional agents are selected from the group consisting of recombinant interferon alpha 2b, IFN- α , PEG-IFN- α -2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil.

90. A method for treating hepatitis B in a subject comprising administering to the subject in need thereof an effective amount of a compound of any one of Claims 1-80 suffering from hepatitis B.

91. A method for treating hepatitis D in a subject comprising administering to the subject in need thereof an effective amount of a compound of any one of Claims 1-80 suffering from hepatitis D.

92. The method of any one of Claims 90-91, further comprising administering an additional agent selected from the group consisting of an interferon, a nucleoside analog, a nucleotide analog, a sequence specific oligonucleotide, a nucleic acid polymer, an entry inhibitor and a small molecule immunomodulator.

93. The method of Claim 92, wherein the additional agent selected from the group consisting of recombinant interferon alpha 2b, IFN- α , PEG-IFN- α -2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide and tenofovir disoproxil.